CLIN. CHEM. 39/9, 1764-1779 (1993)
Total Homocysteine in Plasma or Serum: Methods and Clinical Applications
Per M. Ueland,”5
Allen2
Total homocysteine
Helga Refsum,’
Sally P. Stabler,2
M. Rene Malinow,3
is defined as the sum of all homocys-
teine species in plasma/serum, including free and proteinbound forms. In the present review, we compare and
evaluate several techniques forthe determination of total
homocystelne. Because these assays include the conversion of all forms into a single species by reduction, the
redistribution between free and protein-bound homocysteine through disulfide interchange does not affect the
results, and total homocysteine can be measured in
stored samples. Total homocysteine in whole blood increases at room temperature because of a continuous
production and release of homocysteine
from blood cells,
but artificial increase is low if the blood sample is centrifuged within 1 h of collection or placed on ice. Different
methods correlate well, and values between 5 and 15
mol/L in fasting subjects are considered normal. Total
homocysteine in serum/plasma is increased markedly in
patients with cobalamin or folate deficiency, and decreases only when they are treated with the deficient
vitamin. Total homocysteine is therefore of value for the
diagnosis and follow-up of these deficiency states and
may compensate for weaknesses of the traditional laboratory tests. In addition, total homocysteine is an independent risk factor for premature cardiovascular diseases.
These disorders justify introduction of the total homocysteine assay in the routine clinical chemistry laboratory.
IndexIng Terms: cobalamin, folate deficiencies
.
sample handling . reference values
thiol compounds
hew? disease
enzyme metabolism
amino acids
nutritional status
Homocysteine
(Hey) determination
was introduced
into laboratory
diagnosis
in 1962 when the first patients
with the inborn error homocystinuria
were described (1,
2).6 These patients excrete large amounts
of homocys‘Department
of Pharmacology and Toxicology, Armauer Hansens Hus, University of Bergen, N-5021 Bergen, Norway. Fax 47.
5-973115.
2Division of Hematology,
Department
of Medicine, University
of Colorado Health Sciences Center, Denver, CO.
3Oregon Regional Primate Research Center, 505 NW 185th
Ave., Beaverton, OR
4Department
of Clinical Chemistry, University Hospital,
S-22 185 Lund, Sweden.
5Author for correspondence.
6Nonstandard
abbreviations:
ABD-F, 4-(aminosulfonyl)-7.fluoro-2,1,3.benzoxadiazole-4-su]fonate;
GC-MS, gas chromatography-mass spectrometry; Hcy, homocysteine; mBrB, monobromobimane; and SBD-F, ammonium-7-fluoro-2,1,3-benzoxadiazole-4sulfonate.
Received December 14, 1992; accepted March 24, 1993.
1764
CUNICAL CHEMISTRY, Vol. 39, No. 9, 1993
Anders
Andersson,4
and Robert
H.
tine into the urine, and the blood concentrations become
extremely
high (3). The high concentrations
could be
determined by simple chemical tests (4) or by amino
acid analysis.
Hey in the acid-soluble fraction of plasma/serum
(free
Hey) was detected in healthy subjects with the secondgeneration amino acid analyzers that became available
in the middle 1970s (5, 6). The first clinical studies on
the relation between moderately increased plasma Hey
and increased risk for cardiovascular
disease, published
in the late 1970s and early 1980s, were based on this
methodology (7-9).
Progress in Hcy research during the last 7 years has
been greatly facilitated
by the introduction of improved
techniques
for measuring
Hey in plasma and serum
(10-19). These methods measure total Hey, which is the
sum of protein-bound and free Hey. The main advantage
is that stored samples can be analyzed because total Hey
is not altered when samples are kept frozen, even for
years (B. Israelsson et al., 1992, unpublished). Total Hey
is measured in all studies of Hey as a marker of vitamin
deficiency states (20,21) and in most studies of Hey and
cardiovascular
disease (22).
To date, -20 clinical
studies involving
>1800 patients and an equal number of control subjects
have
demonstrated
that a moderate increase of serum/plasma
Hey is an independent risk factor for premature
cardiovascular
disease. Above-normal plasma Hey has been
found in -30% of the patients with premature
cardiovascular
disease who lack the traditional
risk factors
(22-24).
Since 1985, the value of plasma/serum
Hey determination in the diagnosis and follow-up of folate or cobal-
amin deficiencies has been established. These deficiency
states are probably the most frequently encountered
causes of marked increases of serum/plasma
Hey (2528).
Here we review the methodologies for measuring
total Hey in plasma/serum and their feasibffity as routine
methods in the clinical chemistry laboratory. In the last
part of the article, we evaluate total Hey as a marker of
human disease, with emphasis on folate and cobalamin
deficiencies.
BIochemIstry
Intracellular
formation,
metabolism,
and release of
Hey into the extracellular
compartment
determine the
concentration
of Hey in extracellular
media (e.g., plasma/serum),
which in turn is the basis for measuring
Hey as an extracellular
marker for human disease. In discussing these processes we will emphasize those that may affect the concentrations of extracellular Hey.
Enzymes
involved. Hey is formed as a product of the
adenosyihomocysteinase
(S-adenosylhomoeysteine
hydrolase; EC 3.3.1.1) reaction, which is responsible for the
removal of S-adenosylhomoeysteine,
a product of S-adenosylmethionine-dependent
transmethylation
(29).
Intracellular
Hey is either remethylated
to methionine, converted to cystathionine,
or exported from the
cells. The first reaction is catalyzed by the enzyme 5-methyltetrahydrofolate-Hey
methyltransferase
(methionine synthase; EC 2.1.1.13). This enzyme is ubiquitously
distributed
in mfimmAlian cells. It requires cobalamin as
cofactor and catalyzes a reaction in which Hey remethylation is coupled to the conversion of 5-methyltetrahydrofolate
to tetrahydrofolate;
it thereby operates at a
point of convergence of folate metabolism and the transplasma/serum
methylation/transaulfuration
pathway.
An
alternative
route of Hey remethylation is confined to the liver: In this
reaction,
catalyzed
by betaine-Hcy
methyltransferase
(EC 2.1.1.5), betaine serves as methyl donor (30, 31).
The vitamin
B6-dependent enzyme cystathionine
f3-synthase
(EC 4.2.1.22) catalyzes the condensation of
Hey with serine to form cystathionine. The reaction is
irreversible under physiological conditions, and from
this point on Hey is committed
to the transsulfuration
pathway. Cystathionine is further cleaved to cysteine
and a-ketobutyrate, catalyzed by another vitamin B6dependent enzyme (y-eystathionase; EC 4.4.1.1); this
reaction completes the transsulfuration pathway (31).
Enzyme regulation and Hey distribution
between pathways. Hey is metabolized by either catabolizing enzymes
or methionine-conserving
enzymes; the distribution between these competing pathways is determined by the
Km for Hey, the regulatory effect of S-adenosylmethionine, and the enzyme concentrations. The differential
Km and metabolite regulation are processes that are put
into immediate action in response
to variable methionine availability,
whereas up-regulation of enzyme synthesis is a slow adaptive process (31).
Cystathionine
-synthase
and y-cystathionase are
Hey-catabolizing enzymes, for which Km values are >1
mmol/L. Cystathionine /3-synthase is activated by S-adenosylmethionine,
and the concentrations of both enzymes increase in response to excess dietary methionine. These properties ensure both immediate and longterm drainage of excess Hey via the tranasulfuration
pathway (31).
The Hey-remethylating enzymes,
5-methyltetrahydrofolate-Hey methyltransferase and betaine-Hey methyltransferase, have low Km values for Hey (<0.1 mmol/L).
The activity is (directly or indirectly) inhibited by S-adenosylmethionine, and increased dietary methionine decreases the activity of the former enzyme. These properties favor methionine conservation at low Hey concentrations(31).
Hey export. The release of Hey into the extracellular
medium
represents the third route of cellular Hey dis-
posal and is particularly
important in relation to the
plasma concentration of Hey. Studies with isolated cells
show that Hey export into the extracellular
medium
reflects an imbalance between Hey production and metabolism (32, 33). When cells are cultured in the presence of excess methionine, Hey export from most cell
lines is enhanced (33); this phenomenon resembles the
response to the methionine loading test. Pharmacological (34) and cell genetic studies (B. Christensen
et al.,
unpublished) show that the activity of methionine synthase is critical for Hey export at low methionine concentrations, whereas cystathionine /3-synthase activity
influences the export at high methionine
concentrations. The clinical corollary is that methionine synthase
activity determines the concentration of fasting plasma
Hey, whereas a defect in cystathionine /3-synthase results in an abnormal response to methionine loading.
This model is supported by clinical data showing that
fasting plasma Hey is markedly increased in patients
with folate (25,26, 35) or cobalaniin deficiency (21,25,
35) but is usually normal in vitamin B6 deficiency (36).
Cobalamin-deficient patients and one patient with methylenetetrahydrofolate
reductase
deficiency had normal increases in plasma Hey after methionine loading
(37), whereas patients who were homozygotes (3, 38) or
obligate heterozygotes (39, 40) for cystathionine
/3-synthase deficiency showed an abnormal response.
Different Forms of Hcy In Human Plasma: Implications
for Hcy Determination
In the first studies of plasma Hey in healthy subjects
(5, 41) and in some early clinical studies (20), Hey was
measured in the acid-soluble fraction of plasma as Heycysteine mixed disulfide. However, a major fraction of
Hey in serum/plasma
is associated with plasma protein(s) (42), and probably forms a protein-Hey mixed
disulfide with albumin
(10). This fraction represents
-70% of total Hey in human
plasma/serum
from
healthy subjects (10). Only trace amounts of reduced
Hey (11,43,44)
and the disulfide homocystine (45) have
been demonstrated.
The sum of all Hey species in
plasma (free plus protein-bound) is referred to as total
Hey.
The protein binding of Hey in plasma has some
unique features. Both experimental
(46,47) and clinical
studies (48) demonstrate the presence in plasma of binding sites for aminothiols, which interact preferentially
with Hey. In contrast to cysteine, binding of Hey to
plasma proteins seems to be saturable,
with a maximal
capacity of -140 imol/L (48). This implies that the free
fraction of Hey increases more than protein-bound Hey
does when total Hey is markedly increased. During the
brief hyperhomocysteinemia
induced by methionine
loading, only a moderate, transient increase in the free/
bound ratio occurs. This indicates that a rapid equilibrium exists between free and protein-bound fractions in
vivo (20).
The association of Hey with plasma proteins has important implications for Hey measurements. Free Hey
becomes progressively bound to plasma
protein(s) ex
vivo. Such redistribution takes place within 24 h at
room temperature. Also, most Hey in stored plasma is
CUNICAL CHEMISTRY. Vol. 39, No. 9, 1993
1765
protein-bound.
Reliable measurement of free Hey requires immediate
acid treatment and centrifugation
of
plasma (49). This is impractical
in the clinical setting,
valent metals and inhibits oxidation. Hey is also kept in
its reduced state by the presence of other thiols or by
resupplementation of reductant (43). In the GC-MS as-
and determination
doned.
say, inclusion of deuterium-labeled
Hey as the internal
standard corrects for reoxidation (12). Using a different
sulfur compound as the internal
standard
does not seem
feasible because the rate of oxidation of the internal
standard
may differ from that of Hey (54).
Derivatization
and detection. All methods except those
based on eleetrochemical
detection depend on derivatization of Hey. Precolumn
derivatization with fluorogenie reagents
for thiols followed by HPLC has become
increasingly popular (55). Useful reagents must form
Hey adducts with sufficient fluorescent yield to measure
Hey at picomolar concentrations
or less. Furthermore,
the ideal reagent should be nonfluorescent, contain no
fluorescence
impurities,
and react rapidly and specifically with Hey and other thiols to form stable products.
No reagent meets all these requirements,
but among the
fluorogeme reagents available,
bimanes
and halogenosulfonylbenzofurazans have been found practical
(Figure
1).
mBrB couples rapidly with thiols at pH 8.0 at room
temperature
to produce a highly fluorescent
thioether
(56). One drawback is that the reagent itself, the hydrolysis products, and the impurities are fluorescent (51).
These materials
give rise to several reagent peaks that
may interfere with Hey determination
(14). Removal of
excess reagent is included in some methods (15, 56).
SBD-F and ABD-F are halogenosulfonylbenzofurazans
that have been used for determination
of thiols, including
Hey (57). ABD-F reacts quantitatively
with thiols, including Hey, at 50#{176}C
at pH 8.0-9.5 for 5-10 mm (58), whereas
the less-reactive SBD-F requires more drastic conditions
(pH 9.5 and 60#{176}C
for 1 h). SBD-F is not reactive towards
of free Hey has largely
been aban-
General ConsIderatIons of Methodology
Notes on chemicals.
Some batches of DL-Hey contain
large amounts (about 30%) of impurities, whereas L-homocystine from several suppliers seems to be pure. S-Adenosythomocysteine hydrolase from rabbit eiythrocytes
used
for the radioenzymie assays is occasionally available from
Sigma Chemical Co. (St. Louis, MO) or can be prepared
from liver of the mouse (50) or rat. Any adenosine deeminase present in the enzyme preparation is inhibited by
2’-deoxycoformyein (Pentostatin;
Parke-Davis
Research
Labs., Ann Arbor, MI). Deuterated
Hey used as internal
standard in the gas chromatography-mass
speetrometry
(GC-MS) assay (12) is available
from CJ)
Isotopes
(Va#{224}dret’il,
Quebec, Canada), as are stable isotope-labeled
forms of other metabolites
that can be assayed with this
technique. Monobromobimane (mBrB) contains fluorescent impurities, the amount of which varies from one
batch to another. This reagent is occasionally available
from Calbiochem-Behring
Diagnostics (La Jolla, CA), but
can regularly
be supplied by Molecular Probes (Eugene,
OR); the product of Molecular Probes is also of relatively
high purity. 4-(Aminosulfonyl)- and axnmonium-7-fluoro2,1,3-benzoxadiazole-4-sulfonate
(ABI)-F and SBD-F, respectively) are products of Wako (German Branch, Neuss,
Germany).
Reduction.
Determination
of total Hey in plasma/sethe reduction of the disulfide bond between Hey and other thiols or albumin. Reductants
must be prepared
immediately
before use, and attention
should be paid to stability
during automated unattended sample processing. The selection of reduetant
depends on the separation and detection system used.
Sullhydryl-containing
reducing agents such as dithioerythritol, dithiothreitol,
and mercaptoethanol
liberate
Hey from various disulfIdes. These reductants form adducts with thiol-specific reagents and therefore may
consume derivatization
reagent (51). Sodium or potassium borohydride
is a potent reduetant.
The reduction
takes a few minutes at high concentrations (1.4 mo]/L)
(14), but requires up to 30 mm (15) or heating (52) at
lower concentrations (40-100 mmol/L). Formation of
gas and foaming during the reaction may impose practical problems, especially with regard to automatization, but this can be overcome by adding a surface-active
agent, e.g., octanol. Tri-n-butylphosphine
does not react
with thiol-specific
reagents nor does it form gas during
reaction; however, it consumes fluorogenic reagent
(mBrB) both at 50#{176}C
and at room temperature
(53) and
is an irritant
with an unpleasant odor.
Reoxidation.
Hey formed during the reduction step
can be reoxidized
before derivatization or detection, and
variable reoxidation
is a source of erratic results. Thiol
oxidation is catalyzed by many transition metals (54);
inclusion of EDTA in the reaction mixture chelates dirum
requires
1766 CUNICALCHEMISTRY,Vol.39, No. 9, 1993
P
0
RSB
)-N--k..
.
e
470 am
RSH2C
mBrB
SR
N
RSH
\
0
gL3SOJuS
eai 510am
S03-NH4
SBD-F
SR
RSH
N
N
SO2NH2
ABD-F
Fig. 1. Fluorogenic thiol(RSH)-specffic reagents for precolumn de-
rivatization of Hcy
The excitation and emission wavelengths
for the derivatives are listed
amines (59), whereas ABD-F also derivatizes amines but
with a low fluorescence yield (57).
The low reactivity of SBD-F may cause some problems because of Hey reoxidation,
and assays based on
this agent may be difficult to automatize. However, unreacted benzofurazans
are not fluorescent,
the thiol adducts are stable, and no fluorescent hydrolysis products
are formed. Their use results in clean chromatograms
with no reagent peaks.
The formation of tert-butyldimethylsilyl
derivatives
for GC-MS (12) is not affected by traces of moisture, and
these derivatives are stable at room temperature
for
many weeks.
Automatization
automatization
put is required
and 8ample output. A high degree of
is advantageous,
and high sample outfor methods used in routine laboratory
diagnosis.
Most of the present
tion involve manual
methods for total Hey determinaprocessing
of the samples before
chromatography.
A fully automated
procedure
carried
out in a sequential manner implies no centrifugation
or
filtration of sample, and the reduction and derivatization of Hey must be rapid. The combined use of NaBH4
and mBrB fulfills these criteria and has been successfully implemented in a fully automated
procedure
(14),
as will be described below.
Development of an automated procedure based on derivatization
with a halogenosulfonylbenzofurazan
is
possible and should be undertaken.
The long reaction
time and heating required because of the low reactivity
of SBD-F may cause problems, whereas ABD-F may be
a suitable
reagent.
Assay procedures
based on electrochemical detection can also be fully automated as long
as attention
is paid to detector
stability
and maintenance.
Sample output depends on sample processing
and
chromatographic
retention time. Manual processing of a
large number of samples followed by a rapid chromatographic step gives a high sample output, as demonstrated for GC-MS (12) and for assays based on electrochemical detection (13) or fluorescence detection with
use of SBD-F (18). The long analysis
time of conventional amino acid analyzers,
including
analyzers optimized to detect Hey (16), restricts sample output.
Codetermination
of other metabolites.
Some assays
measure
metabolites
in addition to Hey; this may provide useful data for interpretation
of the results. Methylmalonic acid and 2-methylcitric
acid in serum are
specific markers for cobalamin deficiency and may serve
to differentiate hyperhomocysteinemia
caused by cobalamin deficiency from that due to other causes (21, 60).
The concentration of cysteine in serum shows a complex
relation to Hey, both in homocystinuries
(48,61,62)
and
healthy persons (44, 63); in one recent study, the ratio
between Hey and cysteine correlated
better with serum
folate than did plasma Hey itself (64). Because methionine intake causes an increase in methionine concentration in blood, which is followed by a transient
hyperhomocysteinemia,
knowledge of the methionine concentration may be particularly useful when evaluating the
results of a methionine loading
determination
of eystathionine,
test (20). Simultaneous
betaine, and N,N-dimethylglycine may provide additional information on
metabolic alterations caused by folate and cobalamin
deficiency and those caused by inborn errors of metabolism (65, 66). Measurement of N-methylglycine
may
provide a specific marker for folate deficiency (66).
Methods
Radioenzymic Assays
Total Hey in human plasma was first determined
with
a radioenzymatic
assay based on the conversion of Hey
to S-adenosythomocysteine
in the presence of [‘4C]adenosine and S-adenosythomocysteine
hydrolase.
Dithioerythritol was used as reductant, and radioactive
S-adenosythomocysteine
was quantified by HPLC and scintillation counting (10). This assay can also be carried
out with unlabeled
adenosine and ultraviolet detection
at 254 nm.
In two modified assays, S-adenosythomocysteine
is
isolated and quantified by thin-layer chromatography
(67) or paper chromatography (17) instead of HPLC.
The radioenzymic
techniques
are sensitive and specific and can also measure
Hey in urine. The modifications based on thin-layer chromatography
or paper chromatography require inexpensive
equipment
and can be
established
in any laboratory regardless
of resources
available.
The disadvantages
are that tedious manual
processes,
e.g., enzyme incubation,
protein
precipitation, neutralization,
and centriftigation,
are required.
Another drawback is the limited range of this assay,
owing to the consumption of radioactive adenosine present in the assay mixture.
Gas Chromatography-Mass
Spectrometry
The GC-MS method for total Hey developed by Stabler
et al. (12) has been modified recently (65) and is much
simpler than the initial version. The steps before GC-MS
are addition of deuterated
internal standards
in a single
pipetting,
addition of the reductant
dithiothreitol
and
NaOH in a second pipetting, heating at 40#{176}C
for 30 min,
fractionation of sample on a disposable anion-exchange
column, drying, and derivatization with N-methyl -N-(tertbutyldimethylsilyl)trifluoroacetamide.
The tert-butyldimethylsilyl derivatives are separated and quantified by
capillary GC-MS in the selected-ion monitoring mode,
with use of a benchtop GC-MS equipped with an autoeampler. The variable recovery through these steps and the
reoxidation of Hey during sample processing are corrected
for by including deuterated Hey as internal standard,
which results in a highly precise assay. Using semiautomated pipetting equipment,
a single technician
can process 320 samples in 8 h. The capacity of the automated
chromatograph
is about 160 derivatized samples per 24 h.
Figure 2 shows a selected-ion monitoring trace of Hey and
the internal standard in serum.
The lack of total automation and the relatively high
cost of the equipment are the major disadvantages
of
CUNICAL CHEMISTRY, Vol. 39, No. 9, 1993 1767
cHrl-cH3
H-N
#{182}Hi
cHr--CR3 H3
HHII
nv
CH3ICH3
420
nifz42a3o
-
8
I
‘A
reoxidation
(14).
Excess fluorescent
,m 424.20
6.6
mussen (19): They eluted the SBD-F adducts with a
methanol gradient
and obtained high precision of the
assay by including mercaptopropionylglyeine
as internal standard, which probably corrects for inaccurate
composition of the assay mixture or variable injection
volume. However, this compound elutes after 15 min,
and significantly
prolongs the run time.
The SBD-F-based methods are sensitive and specific,
and there are no interfering reagent peaks in the chromatogram (Figure 3). Disadvantages
include the low
reactivity
of SBD-F and the long reaction time and high
temperature (60 #{176}C)
required.
The derivatization is carried out manually,
but the stability of the adduets allows autoinjection.
mBrB has been used for determining
Hey in plasma
(14, 15). NaBH4 is used as a reductant,
and a high
concentration is required to obtain maximal fluorescent
yield (53). The presence of dithioerythritol
during the
reduction and derivatization increases
the linearity of
the assay in the lower range, probably by preventing
I
.
6.7
6.8
6.8
Retention tine (miii)
FIg.2. Determination of Hey in human serum byGC-MS
mBrB has been removed by treating the sample with thiol Sepharose (15, 56). Sufficient
resolution of the Hey adduct is also obtained after sample clean-up by solid-phase extraction (15) or column
switching (14). However, thiol Sepharose
treatment
and
solid-phase extraction are tedious procedures. Column
switching requires
two solvent-delivery
systems, and
The structure of the tevf-butyldimethyisllylderivative of Hcy and the site of
major fragmentallon during mass spectroscopy are shown. The Hcy part of the
formula Is shown In bold type. The uppertrace Is a selected-Ion monitoring
recording for the ion m/z 420.3, which represents endo9enous Hcy in serum
(6.3 unoUL). The lower trace is a selected-Ion monitoring recording for the ion
rm’z424.3, representing the internal standard, which contains four deutetlum
atoms. Details are given in references 12 and 65
method. Attractive features
are high sensitivity
and specificity, codetermination
of cysteine, methionine,
cystathionine,
N,N-dimethylglycine,
and N-methylglycine (65, 66), and the fact that the assay has been verified for urine samples (12). With a slight modification,
methylmalonic
acid (60), 2-methylcitric acid (60), and
betaine (66) in serum can also be determined.
this
Precolumn
Derivatization,
HPLC, and Fluorescence
Detection
I
Is
In the method of Araki and Sako (11), Hey is derivatized with SBD-F, and the Hey, eysteine, and eysteinylglycine adducts are separated
and quantified by gradient elution of a reversed-phase
column within 12 mm.
This method has been improved by Ubbink et al. (18),
who obtained baseline
separation
of these adduets
within 6 mm by isocratic elution on a reversed-phase
column at pH 2.1. Their system ensures high sample
output, but the low pH of the mobile phase increases
dissolution of the silica matrix. A silica saturation column mounted in front of the injector or a guard column
may reduce this process, and is recommended. Another
modification
has been constructed
by Vester and Ras1768
CUNICAL CHEMISTRY, Vol. 39, No.9, 1993
Retention thne (miii)
FIg. 3. Determination of Hey and other thiols in human plasma by
automated precolumn denvatization with SBD-F
The plasma contained -10 pmol/L Hcy. Details of the chrornatographicconditions are described in reference 19. Cys, cystelne; CysGIy, cystelnyiglycine;
OSH, giutathione; IS, internal standard
(mercaptopropionylgiyclne)
the pressure surge during switching causes column doterioration and short column life.
A fully automated method for the determination
of
plasmR Hey based on NaBH4 reduction
and derivatization
with mBrB was developed by Refsum at al. (14). To increase the reliability
of this method, an improved procedure has been worked out
in which the column
switching is omitted by taking advantage
of the marked
pH dependence of the retention of several mBrB derivatives in reversed-phase
chromatography.
Baseline separation of Hey, cysteine, and cysteinyiglycine
is obtained by
elutung the column with an ammonium
formate buffer
adjusted to pH 3.65 (49) (Figure 4).
Total plasma Hey has recently been assayed with
modifications of the method currently used for amino
acid determination,
which is based on precolumn
de-
rivatization with o-phthaldialdehyde followed by HPLC
and fluorescence detection (52, 68). Two assays have
been published, and in both, plasma is treated with a
reductant,
Hey is carboxymethylated
with iodoacetate
before derivatization with o-phthaldialdehyde,
and homocysteic acid is used as internal standard. The major
differences between these assays are the reductant used
and the retention times (10 and 22 miii) for Hey. When
2-mercaptoethanol
is used, it reacts with iodoacetate,
which must be added in excess (68). However, NaBH4
might increase the complexity of the sample-handling
procedure of these assays, particularly
the generation of
excessive frothing (68). Both techniques include several
manual steps (reduction, deproteunization,
carboxymethylation, pH adjustment, derivatization),
and are not
suitable for automation. The performance
of the assays
is satisfactory.
The widespread
experience
with the
o-phthaldialdehyde
techniques
and the possible determination
of other aminothiols
and amino acids (including cysteine and cysteinylglycine)
are attractive
features
of these methods (52, 68).
HPLC and Electrochemical
Detection
HPLC coupled to an electrochemical
detector is well
suited for the determination
of biological thiols (45, 69),
including Hey (70, 71). This technique has been refined
for assay of total Hey in plasma by Malinow et al. (13),
who modified the method of Smolin and Sneider (72).
NaBH4 is used as a reductant,
and no derivatization
of
sample is required. Thiols in the column effluent are
detected by a single gold-mercury
electrode,
which affords great specificity towards sulihydryl components.
This assay has been optimized for the determination
of
Hey, which elutes at about 4.3 mm (Figure 5), and
samples can be assayed every 10 miii (13). The chromatographic system can be modified to resolve cysteine,
Hey, and eysteinylglycine
(72). Thus, the electrochemical assay offers several attractive features:
simple sample processing, specificity, autoinjection, short run time,
large sample throughput, and the possibility of determination of other thiols (e.g., cysteine).
One major weakness with the electrochemical
assay is
related to contamination
of the flow cell and deterioration
I
Retention time (rain)
FIg. 4. Determination of Hey and other thiols in human plasma by
Retention time (miii)
FIg.
Determination of Hey in human plasma by HPLC and elec-
automated precolumn denvatization with mBrB
The plasma contaIned -10 tmoUL Hcy. The column is eluted with a mobile
trochemical detection
phase adjusted to pH 3.65. Other details of the chromatographic conditions
described in reference 49. Abbreviations as In FIg. 3
The plasma contaIned -10 pmol/L Hey. Details of the chromatographic conditions are described in reference 13. CysGIy, cystelnylglycine
are
5.
CUNICAL CHEMISTRY, Vol. 39, No. 9, 1993 1769
of the gold-mercury electrode. Stability of this assay dopends on careful maintenance of the detector system.
AminoAcidAnalyzer, Postcolumn Derivatization
Determination
of total Hey with a conventional
amino
acid analyzer requires the conversion of the disulfide forms
into reduced Hey. 2-Mercaptoethanol (73) and dithiothreitol (16) have been used as reducing agents. Reduced Hey
has been S-carboxymethylated
by using iodoacetic acid
(73). Alternatively,
Hey has been chromatographed
directly; under those conditions, Hey is protected against
reoxidation by the sulfosalieylic acid (74) used for protein
precipitation, by the presence of reducing agent in the
sample, and by the low pH of the mobile phase.
Hey is eluted with a standard program for physiological
fluids (75), which also permits quantification
of cysteine,
methionune, and eystathionine
(Figure 6). The elution program is interrupted
after the elution of eystathionune and
a 16-mm column regeneration period follows.
The determination of Hey by a conventional amino
acid analyzer has been optimized by Andersson et al.
(16). The samples are treated
with dithiothreitol
(40
mmol/L plasma)
and Hey is analyzed in its reduced
form. Lack of homocystine
disulfide indicates
that no
reoxidation
takes place before or during the chromatography. The method also measures methionine and cystathionine, which elute close to Hey (16). The retention
time of Hey (25.6 miii) and the time for column regeneration limit sample capacity, which is low compared
with the HPLC assays. The construction
and performance of the optimized method are shown in Table 1.
The sensitivity limit (-1 mol/L in plasma) is less
than that of other methods,
but is sufficient for the
determination
of Hey in 0.5 mL of plasma; the impreei-
sion is 5-6% (16). A drawback is the nonseleetivity
for
sulfur amino acids. In plasma samples frozen at -20 #{176}C
for 10 years, nunhydrin-positive
material interfered
with the Hey peak, and the measured Hey values were
about half of those obtained with a specific HPLC
method (B. Israelsson et al., 1992, manuscript
submitted). This may prohibit using the amino acid analyzer
for determination
of Hey in stored samples in prospective studies. However, in plasmas stored at -70 #{176}C
for
several years, no interfering peaks have been observed.
The sample preparation
is simple, and the technical
staff often is well experienced in operating an amino
acid analyzer, which is part of the routine instrumentation in many hospital laboratories.
These facts justify
the use of the ninhydrun-based
Hey assay in the routine
laboratory.
Andersson et al. (76) recently described a method for
plasma Hey that also measures
eysteine, eysteinylglycue, glutathione,
and glutamylcysteine.
The assay
involved reduction of sample with dithiothreitol,
separation of the thiols by HPLC, and postcoluinn
derivatization with 4,4’-dithiodipyridune
and colorimetric detection at 324 nm. The method is characterized
by high
precision.
The baseline fluctuation in this method reflects differences
in absorbance between reagent and
mobile phase. Therefore, the baseline noise is minimized by cooling the reagent reservoir to avoid hydrolysis and by delivering the postcolumn reagent with low
pulsation flow.
CorrelationStudies
Satisfactory correlation exists between the concentrations of plasma Hey obtained by different methods. Values obtained with an automated
mBrB assay (y) (14)
have been compared with those obtained (x) with a
radioenzymic
assay (10) (y = 1.009-x
1.05, n = 160, r
=
0.989) (14), an amino acid analyzer (16) (y = 0.85x +
1.88, n = 133, r = 0.975) (14), and electrochemical
detection (13) (y = 0.85x + 1.11,r = 0.93).Acorrelation
study has also been performed between values obtained
with the electrochemical
detection/HPLC
assay (x) of
Malinow et al. (13) and with an amino acid analyzer
(16) (y = 0.99x
0.69, n = 133, r = 0.95) (77).
Published methods for the determination
of total Hey
are listed in Table 2, and the performance
and practicalities of five methods are compared in Table 1.
-
VII
I
-
Sample Collection and Stability
Effect of FoodIntake
Retention
Fig. 6. Determination of Hey In
time (mm)
human plasma
with an amino
acid
analyzer
The plasma contained -10 unoVL Hey. The chromatogrephic conditions are
In accordance with the standard program of the manufacturer (Blotronlc LC
5000; Blolronic GmbH, Munich,Germany) for amino acids In physiological
fluids. Hey, homocystelne; Cysts. cystathionine; Met, methlonine; Val, valine
1770 CLINICALCHEMISTRY, Vol. 39, No. 9, 1993
The data on possible diurnal variation in plasma Hey
and its relation to normal food intake are sparse and
inconsistent. Malinow et al. (13) found no difference in
total Hey concentrations
in fasting and nonfasting
plasma from 13 subjects; Ubbink et al. (78) found a
small but significant decrease in total plasma Hey 2-4 h
after consumption
of a normal breakfast with the values
returning to normal after 8 h. Ubbink et al. suggested
that the postprandial
decline in plasma Hey could be
Table 1. Charactei1stIcs
Instrument
Requirements,
and Performance
in Plasma
of Five Methods
for Determination
of Total
Homocystelne
Assay
Method (and
Sanipi.
ui(,ce)
vat, mL
GC-MS (12,85)
0.1
Step
Plpetting
Reduction
Solid-phase
Dr1ng
0.15
derivatization
with SBD-F,
HPLC,and
fluorescence
detection (19)
Precolumn
derivatizatlon
with mBiB,
0.1
HPLC, and
Tins,
n*t
Aad
meted
-
Typ.
Vacuurn-dring
centrifuge
-
GC-MS
-
30
extraction
5
Dedvalization,
heatIng
90
30
Injection interval
Precolumn
Insment
chaot&I
30
20
60
Plpetting
Reduction
Dedvatization
Injection interval
3
3
18
0.2
electrochemical
detectIon (13)
Aminoacid
0.5
anatyzer(16)
Plpetting
Reduction
Deprotolnlzallon
Injection Interval
Pipetllng
Reduction
Deproteinizallon
Injection interval
56000
+
-
15
Other no1le.
dilsnnlnsd
Cystathlonine
Methionine
CV for
Hcy, S
Cystelne
-
lLMethyIgIdne
N,NDlmethy$gIdne
Betairec
Meth1malonlc acldc
2-Methylcitric addc
Cysteine
Cysteinylglycine
HPLC pump
Autolnjector
Detector
Integrator
15000
15000
9000
5000
90
HPLC pump
Gilson 232 sample
injector
Detector
integrator
15000
17000
80
Cystelne
Cysteinylglydne
5000
90
Cysteinylglydne
3-1
15000
7000
5000
65000
24
Methlonine
Other amino acids
51
+
+
+
+
+
fluorescence
detectIon (49)
HPLC and
Capecfty
(nwi*sr/24 h)
160
-
7
Pipetting
Reduction
Deprotelnizatlon
Derivatization, healIng
Injectioninterval
Price
(US $)
7000
-
HPLC pump
-
Autolnjector
30
20
-
10
+
Detector
Integrator
Amino acid analyzer
9000
5000
60
30
60
1b
+
1lntraassay CV.
b interaasay CV.
Slight modifications are required for the codeterminatlon of these metabolifes (see references in the text).
Table 2. ConstructIon
of Assays
Reduction agent
for Total Hcy In Plasma/Serum
Separation principle
Ref.
Radioenzymatic assays
Dithioerythrltol
Enzymlc conversion to
HPLC
Absorbanceat 254 nm or
scintillationcounting
Scintillationcounting
10
Mass spectrometnj
(single-Ionmonitoring)
12, 65
11, 19, 18
HPLC
Fluorescence
Fluorescence
Fluorescence
HPLC
fluorescence
52
HPLC
Fluorescence
68
HPLC
Electrochemicaldetection
13, 46
Ionexchange (amino
acid analyzer)
Ionexchange (amino
acid analyzer)
HPLC
Ninhydrinreaction
73
Ninhydrinreaction
16
Reaction with
76
,,-Mannvthnmnrvetair,a
Dithioerythrltol
Enzymicconversionto
S-adenosylhomocysteirte
Gas chromatography-mass
Dfthlothreftol
spectrometly
te,t-Butyldimethylsllyl
derivatizatlon
Capillary
Precolumn derivatization, HPLC, and fluorescence detection
TrI-n-butylphosphlne
SBD-F
Sodium borohydride
Potassium
borohydride
Potassium
borohydnde
2-Mercaptoethanol
mBrB
mBrB
lodoacetic
Thin-layer
chromatography
GC
HPLC
HPLC
acid,
17, 67
14, 43, 49
15
o-phthaldialdehyde
lodoacetic acid,
o-phthaldlaldehyde
HPLC and electrochemical detection
Sodiumborohydride
None
Amino acid analyzer, postcolumn derivatizatlon
2-Mercaptoethanol
S-Carboxymethylation
lodoacetic acid
Dithiothreitol
None
Dithiothreltol
None
with
4,4’-dithiodipyrldlne
CUNICAL CHEMISTRY, Vol. 39, No.9, 1993
1771
attributed to an increased remethylation
rate induced
by the other nutrients
in the meal.
In a study of 11 students, plasma Hcy increased slowly,
reaching a maximum increase of about 15% by 6-Sb after
dinner (a steak) (A.B. Guttormsen et aL, unpublished
results). Such a slow Hey responsetoameal
is possibly due
to the time it takes to degrade food proteins into free
amino acids. After dinner, plasma methionine peaked after 3-4 h. In contrast, after peroral methionine loading,
maximum plasma methionine is usually reached within
1-2 h (44, 79), and peak plasma Hey is usually measured
after 4-8 h (20, 44, 79, 80). Thus, both after a meal and
after a peroral methionine load there is a time difference of
about 3-4 h between the maximal plcIRmR concentrations
for methionine and Hey.
These data indicate that intake of food may affect the
concentration
of plasma Hey and that its effect, although small, may persist for several hours.
Stability of Hcy in Whole Blood
Total Hey in serum or plsum’R increases when the separation of serum or plasma from the blood cells is delayed
(12,19,49,
78,81,82). Within 1 hof storage of whole blood
at room temperature, the phuImR and serum Hey concentrations increase by -10% (19, 49, 78, 82). Stabler et a!.
(12) showed that storage of whole blood at room temperaturefor4and24hledtoinereasesinserumHcyof35%
and 75%, respectively.
The increase is of gimilRr mRgrntude (12, 19, 49), or greater (78, 82) in EDTA plasma
These data explain why serum may have a higher Hey
content than does optimally prepared plasma (19).
During storage of whole blood, the rate of release of
Hey from the blood cells is almost constant, independent
of the plasma Hey concentration
(49). Thus, the Hey
release from blood cells may cause particularly
large
errors in the samples with low (i.e., normal) plasma Hey
content,
whereas
the percent increase is moderate
at
higher concentrations (49). Similarly,
after a peroral
methionine load, the percentage of increase during storage of whole blood was less in samples with high plasma
Hey (49).
The blood cells are the source of the Hey increase
storage, because the Hey concentration is stable
in plasma or serum (19, 49, 78). Recently, Andersson et
a!. showed that the erythrocytes
are the major contributors to the artificial increase (82). Because hemolysis
does not change or reduce the concentration
of Hey in
plasma (49, 78), the increase in plasma Hey is presumably due to continuous production of Hey in the erythrocytes, which is then released to the extracellular
compartment.
These data are consistent with the finding of
low intracellular
Hey in most cells (83).
An artificial increase in total Hey is avoided when
blood is put on ice immediately
after collection, or when
plasma or serum is prepared
within 1 h after collection
during
(12, 19, 49, 78, 81, 82).
Plasma
Hey is to a large extent bound to
(10). Because of postural hemodilution,
serum
averages
9% more in the blood collected from
who are standing than from those in the supine
1772
CUNICAL CHEMISTRY, Vol. 39, No. 9, 1993
albumin
albumin
subjects
position
(84). The position may, therefore, affect the measured
Hey values, but this has not been evaluated.
plasma
Stability of Hcy in Plasma
Because Hey in plasma or serum is stable for days
when kept at room temperature
(19,49, 78), transport
of
unfrozen samples to the laboratory
is feasible. Repeated
freezing and thawing procedures
(12, 19, 78, 81) do not
affect the plasma or serum Hey concentration; neither
does freezing for a period of several months (19, 85).
Recently, Hey concentrations
were investigated
in samples kept frozen for an average of 10 years and in fresh
samples from the same individuals
(B. Israelsson et al.,
submitted).
Included in the study were patients (n = 28)
who had been healthy at the first investigation,
but
later suffered a stroke or cardiac infarct, and matched
controls (n = 48). In both groups, the concentration of
Hey in plasma was significantly
correlated
between
stored and fresh samples. Plasma Hey was somewhat
higher in the fresh samples than in the stored ones, but
this may be related to the observed effect of the subjects’
age on the plasma concentration of Hey (77). Not only is
plasma or serum Hey stable in the frozen state for years,
but also the fasting Hey concentration
remains fairly
constant
within most individuals
for years (B. Israelsson et al., submitted).
The stability of total Hey in whole blood and plasma/
serum under various conditions is summarized in Table 3.
Values
The normal values for total Hey differ somewhat from
one laboratory to another (Table 4), but values between 5
and 15 mol/L
are usually considered as normal. The
variability may be related to different methodologies (Table 2), differences in sample processing,
or the selection of
subjects who are under the influence of various factors
that affect the concentration of plasma/serum
Hey.
Total plasma Hey seems to be dependent on age, gender, and, in women, possibly menopausal status (77).
The large differences in cysteine-Hey
disulfide concentrations between pre- and postmenopausal
women reported earlier (6, 86-88)
have not been found when
measuring
total Hey. Total plasma Hey is decreased
by
30-50% during pregnancy
and is normalized within 2-4
days postpartum
(89, 90).
Figure 7 shows the frequency distribution curve for
total plasma Hey in a screened population, showing a
skewed distribution of values.
Reference
Table
3. StabIlity of Total Hcy In Whole Blood and
Plasma/Serum
Sample
Whole blood
Plasma/serum
Sterage condftlens
Room temp.
0-2#{176}C
Room temp.
0-2 #{176}C
-20#{176}C
Data from references
12, 19,49,78,
StabIlity
<1
h
4-12
h
At least 4 days
Several weeks
Years
82, and unpublished results.
Table 4. Normal Values for Total Hcy In Human
Men, a - 3(XJO
Plasma/Serum
a
Age, yearsb
Hcyfractlon
n
Value, gLmol/l
Ref.
± 0.48
10
M
25-55
l8Free
Bound
2.27
F
25-55
16 Free
1.95 ± 0.56
M
<30
Bound
30-39
40-49
50-59
60-69
F
<30
30-39
M+F
F
M9
F”
40-49
50-59
60-69
18-65
19-55
62.9 ± 10.8
5 Bound=totald
14
25
26
23
9 Bound=total”
8
±
38
50 Total
99 Total
45 Total
10.0 45 Total
20-39
40-49
F
20-39
24
2.0 ± 0.9
8.9 ± 3.4
2.0 ± 1.0
9.8 ± 3.0
2.1 ± 0.8
10.0 ± 2.8
11.26 ± 3.71
10.15 ± 4.99
8.01 ± 1.76
9.8 ± 1.6
6.8 ± 1.2
13.3 ± 4.7
9.7 ± 3.3
12.4 ± 2.9
9.1 ± 3.0
50-69’
37 Free
Total
92
Total
167 Total
25 Total
8 Total
8 Total
195 Total
52 Total
40 Total
16 Total
Total
63.4±11.5
M+F
M
22-46
F
25-60
M
M+F
25-60
J300#{149}
200100
0.7
± 2.4
±
21
104
127
7’
0.9
± 2.6
± 0.7
118
128
19
129
Total Hcy in Laboratory Diagnosis
Cobalamin Deficiency
The classical view of cobalainin
(vitamin
B12) deficiency is that it usually
develops at age >60 years;
usually presents with megaloblastic
anemia, macrocy-
50
Fig. 7. Frequency distribution curve for total plasma Hey screened In
3000 men, ages 40-42 years
This population was part of a survey conducted In the county of Hordaland,
Norway, by the National Health Screening Service In collaboration wIth the
University of Bergen. The samples were assayed
reference49
20-60
52
1-38
M, male; F, female,
b Range, or mean ± SD.
#{176}
Hcy equivalents, mean ± SO, except as noted.
d5jJ
Hcy in storedsamples, because free Hcy becomes assoo
ated with plasma protein(s).
#{149}
Mean ± 2 SD after log normalization to correctfor skewness towards
higher values. The samples were allowed to stand at room temperature for 1-4
h before centrifugatlon.
‘Same as exceptthat samples were centrifuged wIthin 1 h of collection.
9Normotensive.
“Hypertensive.
‘PosfrnenopausaL
1Blacktilbe.
M+F
10
20
30
40
TotaLplasma homocysteine (jtmol/L)
0
± 1.4
± 4.6
±
lIJ8pniol/L
4.48 jm,oiiL
Median =
10.70 pmolIL
95th percenllle -17.6 pmoi/L
126
3.2
11.7 ± 2.4
22 Free
56.0±11.3
±
Free
40-49
F
8.1
Free
Total
M
8.82 ± 3.82
9.20 ± 3.62
5.4-1 6.2
5.0-1 3.9
5.8 ± 0.9
Total
26 Free
Total
15 Free
33
7.50
7.8
10.9
2.1
9.7
2.5
10.4
2.8
Total
50-69
8.06
1.28
± 2.32
± 2.00
± 2.02
± 2.32
± 2.02
± 1.64
7.00 ± 1.94
Total
M
8.84
7.26
24
30
Total
63.3
9.44
± 2.62
±
Mean
SD=
400
6.51 ± 1.35
7.29
6.82
8.92
500
wIth the method desc.lbed
in
and hypersegmented
neutrophils;
and is often accompanied by neurological
abnormalities.
In these
cases, the hematological picture was taken as an important diagnostic feature (91). The neurological
abnormalities have long been considered
to be confined to
advanced
deficiency, and to occur only rarely in the
absence of anemia or other hematological
findings. Recent clinical research has demonstrated
that the classical view is wrong and that cobsdtiniin deficiency exists
in a large number of patients with subtle biochemical
changes
and no hematological
abnormalities
(92-94);
moreover, neuropsychiatric
disorders due to cobalamin
deficiency commonly occur in the absence of anemia and
tosis,
macrocytosis(93).
The established diagnostic tests for cobalamin deficiency have some disadvantages.
Serum cobalamin
assays do not completely
discriminate
deficient patients
from normal persons because, by definition, 2.5% of norma.! subjects have low values. Furthermore,
5-10% of
patients with clinically confirmed cobislamin deficiency
have normal values for serum cobalamin
(93,95). Other
procedures,
e.g., bone marrow examination and the cJ.assic Schilling test, may also give false results
(21, 94).
Many cobalamin-deficient
patients fail to absorb protein-bound cobalamin,
but their absorption of the free
vitamin
is normal
(96). The deoxyuridine
suppression
test is too cumbersome
to be included in routine laboratory diagnosis
(97, 98).
Concentrations
of total Hey in plasma/serum
are increased in most patients with cobalamin deficiency (21,
25,28, 35, 93, 94, 99). In a large population
of patients,
some of whom have classical cobalamin
deficiency, serum cobalamin
and plasma Hey concentrations display
a hyperbolic
relation
(Figure 8). The plasma Hey content increases
abruptly when serum cobRbmin
approaches
values
that are below normal
(<130
pmol/L),
but a negative correlation is observed in the normal to
CLINICAL CHEMISTRY,
Vol. 39, No. 9, 1993
1773
70’
that increases rapidly after perturbation of the intracellular cobalamin function. This is demonstrated
in pa-
‘7
50’
40
20
I:
‘r
T
4047
IC’
I-’
0
70
100 130 200 300 5001000 .1000 0
Serum cobelaznin(pinol/L)
2,3
5
73
10
IS
20
30 >30
Serum folale (nmol/L)
FIg. 8. The relation between total Hey and serum cobalamin orserum
folate
Total plasma Hcy, serum cobalamin, and (or) serum lolate concentrations
were determined in 1600 patients admitted to Haukeland University hospital.
The patients were divided into groups according to their cobalamin or folate
values. Eachgroupis definedby the vitamin concentrations given at the base
of each column;thecolumnheight (andbars) indicate the corresponding mean
(± SD) Hcy concentrationsforthatgroup.The numbersat the tops of the
columns indicatethe numberof patients in each group
low-normal range for cobalamin
(130-300 pmoWL). This
observation may suggest that having serum cobalamin
in the normal range does not ensure optimal cobAlamindependent Hey remethylation
in tissues.
Compared
with serum methylmalonic
acid, plasma/
serum Hey is not a specific marker for cobalamin
deficiency: The plasma concentration
of Hey also increases
markedly in other conditions,
including
folate deficiency, which causes indistinguishable
hematological
abnormalities.
The specificity for both tests can be increased by measuring
the metabolite concentrations
before and after treatment
with cobalainin or folic acid,
because the concentration
of Hey and methyhnalonic
acid decreases rapidly towards
normal (within
14 days)
only after administration
of the vitamin that is lacking
(21).
Diagnosis
of the correct vitamin deficiency is very
important:
If a cobalamin-deflcient
patient is mistakenly treated with folate, the hematological
abnormalities may improve or completely
correct, but the neuropsychiatric
abnormalities
will continue to progress
(21, 100).
Clinical
studies show that plasma/serum
Hey is a
sensitive marker of coblilsimin deficiency (101). Hey and
(or) serum methylmalonic
acid concentrations
were increased in 94% of 86 consecutive cobalamin-responsive
patients, many of whom lacked one or more of the classic
hematological
or laboratory
abnormalities
(94). Furthermore, hematological
relapse in patients on infrequent cobalamin maintenance
therapy was associated
with increased metabolite concentrations
in 95% of the
cases, whereas the serum cobalamin was low in only
69%. Serum methylmalomc
acid was somewhat
more
sensitive than plasma/serum
Hey in this study (95).
The sensitivity
of plasma/serum
Hey in comparison
with other diagnostic
tests for cobalamin deficiency is
an important
issue. This question is related to the ability of plasma/serum
Hey to reveal an early deficiency
state. Total plasma/serum
Hey is a responsive marker
1774
CLINICAL
CHEMISTRY,
Vol. 39, No. 9, 1993
tients being anesthetized
with nitrous oxide, which oxidizes cobal(I)amin,
a cofactor for the enzyme methionine synthase; after 90 miii of nitrous oxide exposure, a
significant increase in total Hey is observed (102).
Subtle or atypical cobalamin deficiency seems to be at
least as common as the classical deficiency (103) and
appears to occur often in the geriatric population (104,
105). Its nature is stifi being defined, and the importance of increased
metabolites
requires additional investigation.
Nevertheless,
determination
of plasma/serum Hey is both a sensitive indicator of cobalamin depletion
and an objective
measure
of therapeutic
response.
Folate Deficiency
Folate deficiency is often nutritional
and usually develops in predisposed
subjects such as alcoholics, pregnant women, and patients with generalized
malabsorption. Classical
signs are macro-ovalocytosis,
anemia,
and hypersegmented
neutrophils
(98, 100).
Plasma/serum
Hey is markedly increased in folatedeficient patients (25, 26, 35, 101). In 19 patients with
subnormal
concentrations
of serum folate (<2 gfL),
137 subjects with low-normal concentrations (2-3.9 g/
L), and 44 subjects with normal concentrations
(4-17.9
zgIL), serum Hey was negatively
correlated
with the
serum folate concentration.
In 84% of the patients with
subnormal
serum folate, Hey was 2 SD greater than the
normal mean, and up to 70 tmol/L. Of particular
interest was the observation that more than half of the patients with low-normal serum folate had increased
serum Hey (26). A similar picture is shown for the relation
between
plasma Hey and serum folate in 1620 patients
(Figure 8). This suggests that folate intake that results
in a serum folate content in the lower normal range is
not necessarily sufficient for optimal remethylation of
Hey and that a relative deficiency of tissue folate may
exist under these conditions (26). Data from an experimental model involving rats fed a folate-defieient diet
show that low-normal and subnormal concentrations
of
serum folate cause a two- to fourfold increase in serum
Hey (106).
The possibility
that subjects with no clinical or laboratory signs of folate deficiency may actually be deficient in intracellular
folate is supported by a decrease in
plasma Hey after administration
of high doses of folic
acid. The effect of folic acid was observed both in hyperhomocysteinemic
postmenopausal
women (88) and in
apparently healthy subjects (85).
An increase
in plasma Hey reflects intracellular
folate
deficiency or impaired function of folate-dependent
reactions. The responsiveness
of this factor is demonstrated by the observation
that plasma Hey increases
markedly within hours after administration
of the antifolate drug methotrexate
(80, 107-1 09). Furthermore,
the specificity of plasma Hey as an indicator of folate
deficiency is increased by the simultaneous
determination of serum methylmalonic
acid and by the reduction
of plasma Hey in folate-deficient subjects within weeks
after administration
of folic acid but not after cobalamun
(21).
Plasma
Hey as an indicator of folate deficiency may
compensate for some defects of the conventional laboratory test. Serum folate does not discriminate between a
transitory reduction in folate intake and chronic folate
deficiency associated
with depletion of tissue folate
(110). Furthermore,
both serum and erythrocyte
folate
may be normal in patients with alcoholism and megaloblastic anemia
(111). In addition, assay of red cell
folate has many technical pitfalls: Both the interlaboratory variation and the coefficient of variation have been
high (112). The deoxyuridine
suppression test has been
regarded as a more reliable method than measurement
of either serum or red cell folate for detecting
folate
deficiency (113), but the complexity of the procedure has
prevented widespread use of this technique.
The combined use of serum cobalamin,
folate, total
Hey, and methylmalomc acid concentrations
currently
provides the maximal
utifity in diagnosing and distinguishing between cobalamin
and folate deficiency. Any
of the appropriate tests can give normal results in some
patients
with clinically confirmed cobalamun or folate
deficiency (94, 95), but the use of the panel makes it
possible to make or exclude the diagnosis of cobalamun
or folate deficiency in virtually every patient (101). Nevertheless,
a logistic regression analysis evaluating each
of the four tests would be of interest.
Homocystinuria
Homocystinuria
is a group of inherited disorders characterized by excretion of large amounts of homocystine
into the urine. The most common form is cystathionine
p-synthase
deficiency, which has a prevalence
of
1:200 000 worldwide. Rare forms are caused by various
defects of Hey remethylation, including 5,10-methylenetetrahydrofolate
reductase (EC 1.5.1.20) deficiency and
errors of cobalamin
metabolism. Common clinical signs
in these diverse conditions are mental retardation
and
premature
vascular
disease (114). Homocystinuria
has
been the subject of several recent review articles (3,22,
114).
Determination
of Hey in plasma and homocystine in
urine are laboratory
tests for the diagnosis
of various
forms of homocystinuria.
In patients with cystathionine
fi-synthase deficiency, increases of plasma Hey up to 500
mol/L have been reported (3). These patients also have
large amounts of methionine
in plasma and low or lownormal concentrations
of cystathionine
(65)-important
biochemical features that serve to distinguish these patients from patients with inborn errors of Hey remethylation. Patients with 5,10-methylenetetrahydrofolate
reduetase
deficiency or impaired methylcobalamin
synthesis have high concentrations of Hey in plasma and
urine, normal or subnormal concentrations of plasma
methionine, and high concentrations of serum or plasma
eyst.athionune
(65). Measurement of methylmalonie acid
and 2-methylcitric acid (60) in plasma or urine may
differentiate
reductase
deficiency (with normal concen-
of methylmalonic
acid and 2-methylcitric acid)
from defects in cobalamin metabolism
(in which these
acid concentrations
are increased)
(3).
Measurement of metabolites in plasma and urine may
point to a particular defect of Hey metabolism,
but confirmation of the diagnosis requires determination
of enzyme activities in cultured
fibroblasts. This laborious
technique
has been established
in only a few laborato-
trations
ries(3).
Premature Cardiovascular
Disease
Studies involving -1800 patients and a comparable
number of controls show a statistically
significant
correlation between hyperhomocysteinemia
and premature
cardiovascular
disease
(22). The overall increase
in
plasma Hey in populations
with early cardiovascular
disease is -30% over that in healthy subjects, but shows
some variability
related to the site of the vascular lesions. In coronary artery disease, the ratio for mean
plasma Hey in patients vs controls was 1.2 to 1.3; in
peripheral and cerebrovascular
disease, this ratio varied from 1.5 to 1.8 (24). This distribution of statistical
means is related to the observation that the incidence of
hyperhomocyst(e)inemia
is highest in cerebrovascular
disease [-40% (115, 116)], intermediate
in peripheral
arterial disease [-25% (117)1, and lowest in coronary
heart disease [-15% (118)].
Hyperhomocysteinemia
is a possible risk factor for
premature vascular disease, and is independent of other
factors such as hypertension,
diabetes, smoking, and
plasma cholesterol (20, 22). A causative role of Hey in
atherogenesis
has not been established.
A prospective
study showing a relationship between plasma Hey and
risk of myocardial
infarction
has been published recently (119), and another population-based
prospective
study has been completed (E. Annesen et al., manuscript
submitted). These studies confirm that Hey is a strong
risk factor for myocardial
infarction,
particularly
in the
younger age group. However, no intervention studies,
which are critical for the question of the role of Hey in
atherogenesis, have been conducted.
We propose the tentative
recommendation
that
plasma Hey should be determined
in patients with premature
(age <55 years) cardiovascular
disease, especially in patients who lack other risk factors. The results
from ongoing epidemiological
and proposed intervention
studies may broaden this recommendation
in the future.
and Drugs
Plasma Hey is increased in patients with renal failure. This increase is moderate to marked (up to 50
unolJL) and is positively correlated
to serum creatinune
(20, 120). A moderate increase
of plasma Hey is observed in most patients with psoriasis (81) and in some
patients with leukemia
(109) or solid tumors
(107).
Plasma concentrations are low in some patients with
Down syndrome
(20, 121) and in most patients with
hyperthyroidism
(Lien et al., unpublished).
Some drugs affect the plasma Hey concentration (for a
recent review, see 122). The antifolate drug methotrexOther Diseases
CUNICAL
CHEMISTRY,
Vol. 39, No. 9, 1993 1775
ate, at doses of 25 mg (80) to 8 g/m2 (108, 109), and
nitrous
oxide anesthesia
(30, 102) induce rapid and
transient increases
in plasma Hey. Preliminary
data
suggest that the antiepileptic drugs phenytoin and carbamazepine
induce hyperhomocysteinemia,
probably
due to interference
with folate functions. The cholesterol-lowering regimen of colestipol plus niacin also causes
a significant
hyperhomocysteinemia
(123), possibly
through interference with folate absorption.
Drugs acting as vitamin B6 antagonists
[isoniazide,
cycloserine,
hydralazine,
penicillamine,
pheneizine, and procarbazine (124)] would be expected to increase plasma Hey, as
demonstrated
for the banned drug azauridine
(124).
High doses of folic acid (5 mg daily) cause variable
decreases in high plasma Hey concentrations in patients
with renal failure but also in healthy subjects without
overt folate deficiency (84, 125). The first doses of leucovorin (70 mg/m2), administered
to modulate the effect
of 5-fluorouracil,
induced a marked decrease in plasma
Hey within hours (J. Geisler et a!., unpublished).
and ConclusIon
It is mandatory that a technique
Summary
to be established
in
chemistry laboratory
measures all Hey species
in plasma/serum,
i.e., total Hey. This is a prerequisite
a clinical
for the technique to be compliant with the routines for
sample collection, processing,
and transport
in the clinical setting.
Several new Hey methods have been developed and
old techniques have been refined. The practical aspects
of these techniques are quite different, as summarized
in Table 1. Choice of method depends on the personnel
and instrumental
resources
available, the training
of
the technical staff, the anticipated number of samples to
be analyzed, and special interests
concerning the codetermination
of other metabolites.
Determination
of plasma/serum
total Hey together
with determinations
of other metabolites, such as methylmalonic
acid, is of value for the diagnosis and follow-up of cobalamin
and folate deficiency, especially in
cases of subtle or atypical deficiency, where the classical
signs are lacking. These conditions seem to be rather
common. Thus, the laboratory
diagnosis of cobalamin
and folate deficiency will probably account for the largest number of plasma/serum
Hey determinations.
In
addition, assessment
of risk for cardiovascular
disease
and clinical evaluation of premature
vascular
disease
may become important applications in the near future.
Plasma/serum
Hey also plays a pivotal role for the diagnosis of different forms of homocystinuria,
but these
are rare conditions.
References
1. Gerritaen
homocysteine
T, Vaughn JG, Weisman HA. The identification
of
in the urine. Biochem Biophys Res Commun 1962;
9:493-6.
2. Carson NAJ, Neil DW. Metabolic
abnormalities
detected in a
survey of mentally backward individuals
in Northern
Ireland.
Arch Dis Child 1962;37:505-13.
3. Mudd SH, Levy IlL, Skovby F. Disorders of transaulfuration.
In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic
basis of inherited disease, 6th ed. New York: McGraw-Hffl, 1989:
693-734.
4. Wannmnker
CMD, Weiner M, Giiigliani R, Filho CSD. An
improved specific laboratory test for homocystinuria.
Cliii Clam
Acta 1982;125:367-9.
5. Gupta VJ, Wilcken DEL. The detection of cysteine-homocys.
teine mixed disulphide in plasma of normal fasting man. Eur J
Clin Invest 1978;8:205-7.
6. Wilcken DEL, GuptaVJ. Cysteine-homocysteine
mixed disul.
phide: differing plasma concentrations in normal men and women.
Cliii Sci 1979;57:211-5.
7. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery
disease. A possible role for methionune metabolism. J Cliii Invest
1976;57:1079-82.
8. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia,
ischemic heart disease, and the carrier state for homocystunuria.
Metabolism 1983;32:363-70.
9. BrattatrOm LE, Hardebo JE, Hultberg BL. Moderate
homocysteunemia-a
possible risk factor for arteriosclerotic
cerebrovascular disease. Stroke 1984;15:1012-6.
10. Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocyateine in plasma and urine. Clin Chem 1985;31:
624-8.
11. Araki A, Sako Y. Determination
of free and total homocysteine in human plasma by high-performance
liquid chromatography with fluorescence detection. J Chromatogr 1987;422:43-52.
12. Stabler SP, Marcel! PD, Podell ER, Allen RH. Quantitation
of
total homocysteune,
total cyateine, and methionine
in normal
serum and urine using capillary gas chromatography-mass
spectrometry. Anal Biochem 1987;162:185-96.
13. Malinow MR, Kang SS, Taylor LM, Wong PWK, Inahara T,
Mukeijee D, et aL Prevalence of hyperhomocyst(e)inemia
in patients with peripheral arterial occlusive disease. Circ Res 1989;79:
1180-S.
14. Refaum H, Ueland PM, Svardal AM. Fully automated fluorescence assay for determining
total homocysteine in plasma. Clin
Chem 1989;35:1921-7.
15. Jacobsen DW, Gatautis VJ, Green R. Determination
of plasma
homocysteine
by high-performance
liquid chromatography
with
fluorescence detection. Anal Biochem 1989;178:208-14.
16. Andersson A, Brattstrom
L, Isakason A, Israelsson B, Haltberg B. Determination
of homocysteine
in plasma by ion-exchange
chromatography.
Scand J Cliii Lab Invest 1989;49:445-50.
17. Chadefaux
B, Coude M, Hainet M, Aupetit J, Kamoun P.
Rapid determination
of total homocysteine
in plasma [Tech Briell.
Cliii Chem 1989;35:2002.
18. Ubbink JB, Vermaak WJH, Biasbort S. Rapid high-performance liquid chromatographic
assay for total homocysteine
levels
in human serum. J Chromatogr
1991;565:441-6.
19. Vester B, Rasmussen K. High performance liquid chromatog-
raphy method for rapid and accurate determination
tame
in plasma
of homocys-
and serum. Eur J Clin Chem Cliii
1991;29:549-54.
20. Ueland PM, Refsum H. Plasma homocysteine,
Biochem
a risk factor for
disease: plasma levels in health, disease, and drug therapy. J Lab Cliii Med 1989;114:473-501.
vascular
21.
Our original work cited in this review was supported by The
Norwegian Cancer Society, the Norwegian Council on Cardiovascular Diseases, the Norwegian Research Council for Science and
Humanities,
and the Nordic Insulin Foundation (P.M.U., H.R);
The National Institute on Ageing (AG-09834) (S.P.S.); The National Institute of Diabetes and Digestive and Kidney Diseases
(DK-2 1365) (R.H.A.); The National Institute of Health (RR 0016332) (M.R.M.); and by grants from The Medical Faculty, University
of Lund (A.A.).
1776 CLINICALCHEMISTRY,Vol.39, No.9, 1993
Allen RH, Stabler SP, Savage DG, Lindenbaum
J. Diagnosis
of cobalamin deficiency. 1. Usefulness of serum methylmalonic
acid and total homocysteine
concentrations.
Am J Hematol
1990;
34:90-8.
22. Ueland
PM, Refsum H, BrattstrOm L. Plasma homocysteine
and cardiovascular
disease. In: Francis RB Jr, ed. Atherosclerotic
cardiovascular
disease, hemostasis, and endothelial function. New
York Marcel Dekker, 1992:183-236.
23. Mahnow MR. Hyperhomocyst(e)inemia.
A common and easily
reversible risk factor for occlusive atherosclerosis. Circulation
1990;81:2004-6.
24. Kang S-S,Wong PWK, Malunow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular
disease. Annu Rev Nutr
1992;12:279-98.
25. Stabler SP, Marcell PD, Podell ER, Allen RH, Lindenbaum J.
Serum homocysteine
(Hcy) is a sensitive indicator of cobalamun
(Cbl) and folate deficiency. Blood 1985;66(Suppl):50a.
26. Kang S-S. Wong PWK, Norusis M. Homocysteinemia
due to
foists deficiency. Metabolism 1987;36:458-62.
27. Hall CA, Chu RC. Serum homocysteine
in the routine evaluation of potential vitamin B12 and folate deficiency. Eur J Haematel 1990;45:143-9.
28. Brattstrom L, Israelsson B, Lundgsrde F, Hultberg B. Higher
total plasma homocysteine
in vitamin B12 deficiency than in
heterozygosity
for homocystinuria due to cystathionune -synthase
deficiency. Metabolism 1988;37:175-8.
29. Ueland PM. Pharmacological
and biochemical aspects of S-adenosylhomocysteine
and S-adenoaylhomocysteine hydrolase [Review]. Pharmacol Rev 1982;34:223-53.
30. Frontiera MS, Stabler SP, Kothouse JF, Allen RH. Regulation
of methionune metabolism: effect of nitrous oxide and excess
dietary methionine. J Nutr Biochem 1993;(in press).
31. Finkelstein JD. Methionune metabolism in mammals. J Nutr
Biochem 1990;1:228-37.
32. Svardal AM, Djurhuus R, Refsum H, Uelsnd PM. Disposition
of homocysteine in rat hepatocytes and in nontransformed and
malignant mouse embryo fibroblasts following exposure to inhibitors of S-adenosylhomocysteine catabolism. Cancer Res 1986;46:
5095-100.
33. Christensen
B, Refsum H, Vintermyr 0, Ueland PM. Homocysteine export from cells cultured in the presence of physiological
or superfluous levels of methionine:
methionine
loading of nontransformed,
transformed,
proliferating
and quiescent cells in
culture. J Cell Physiol 1991;146:52-62.
34. Christensen B, Ueland PM. Methionine synthase inactivation
by nitrous oxide during methionune loading of normal human
fibroblasts. Homocysteine remethylation
as determinant of enzyme inactivation
and homocysteine export. J Pharmacol Exp
Ther 1993; (in press).
35. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG,
Lindenbaum J. Elevation of total homocysteine in the serum of
patients with cobalamin or folate deficiency detected by capillary
gas chromatography-mass
spectrometry.
J Clin Invest 1988;81:
teine and other thiol components in plasma during methionine
loading in healthy men. Clin Chem 1992;38:1316-21.
45. Murphy-Chutorian DR, Wexman MP, Grieco AJ, Heininger
JA, Glasaman
E, Gaull GE, et al. Methionine
intolerance:
a
possible risk factor for coronary artery disease. JAm Coil Cardiol
1985;6:725.-30.
46. Smolin LA, Benevenga NJ. Accumulation of homocyat(e)ine in
vitamin B-6 deficiency: a model for the study of cystathionine
-synthase
deficiency. J Nutr 1982;112:1264-72.
47. Smolin LA, Benevenga
NJ. The use of cyst(e)ine in the
removal of protein-bound homocysteine. Am J Clin Nutr 1984;39:
730-7.
48. Wiley VC, Dudman NPB, Wilcken DEL. Interrelations
between plasma free and protein-bound homocysteine
and cysteine
in homocystinuria.
Metabolism 1988;37:191-5.
49. Fiskeratrand
T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Cliii Chem 1993;39:263-71.
50. Ueland PM, D#{248}skeland
SO. An adenosine 3’:5’-monophosphate-adenosine
binding protein from mouse liver. J Biol Chem
1977;252:677-86.
51. Baeyens W, van der Weken G, Lin Lug B, de Moerloose P.
HPLC determination
of N-acetylcysteine
in pharmaceutical
preparations after pre-column derivatization
with Thiolyte5 MB using
fluorescence detection. Anal Lett 1988;21:741-57.
52. Fermo I, Arcelloni C, Devecchi E, Vigano S, Paroni R. Highperformance
liquid chromatographic
method with fluorescence
detection for the determination
of total homocyst(e)ine
in plasma.
J Chromatogr 1992;593:171-6.
53. Baeyens W, van der Weken G, De Moerloose P. Effects of
reducing agents on the determination
of thiolic compounds in the
presence of their disulfides using bimane pre-column derivatization. Chromatographia 1987;23:717-21.
54. Munday R. Toxicity of thiols and disulfides: involvement of
free-radical species. Free Rad Biol Med 1989;7:659-73.
55. Ohkura Y, Nolan H. Fluorescence
derivatization
in highperformance
liquid chromatography.
Mv Chromatogr
1989;29:
221-58.
56. Fahey RC, Newton GL, Dorian R, Kosower EM. Analysis of
biological thiols: quantitative determination of thiols at the picomole level based upon derivatization
with monobromobimanes
and
separation
by cation-exchange
chromatography.
Anal Biochem
1981;111:357-65.
466-74.
36. Miller JW, Ribayamercado
JD, Russell RM, Shepard DC,
57. Imai K, Uzu S, Toyo’oka T. Fluorogenic
reagents,
having
benzofurazan
structure,
in liquid chromatography. J Pharm
Morrow FD, Cochary EF, et a!. Effect of vitamin B-6 deficiency on
fasting plasma homocysteine
concentrations.
Am J Cliii Nutr
Biomed Anal 1990;7:1395-403.
58. Ling BL, Dewaele C, Baeyens WRG. Micro liquid chromatog1992;55:1154-60.
37. Brattstrom L, Israelsson B, Norrving B, Bergqvist D, Th#{246}nne raphy with fluorescence detection of thiols and disulphides. J
J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in
Chromatogr
1991;553:433-9.
early-onset
cerebral and peripheral
occlusive arterial disease59. Imai K. Derivatization
in liquid chromatography.
Adv Chroeffects of pyridoxine
and folic acid treatment.
Atherosclerosis
matogr 1987;27:215-45.
60. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Elevation of
1990;81:51-60.
38 Brenton DP, Cusworth DC, Gaull GE. Homocystinuria:
met2-methylcitric
acid I and!! in the serum, urine, and cerebrospinal
abolic studies on 3 patients. J Pediatr 1965;67:58-68.
fluid of patients with cobalamun deficiency. Metabolism
1993; (in
39. Sardharwalla IB, Fowler B, Robins AJ, Komrower GM. Detecpress).
tion of heterozygotes
for homocystinuria. Study of sulphur-con61. Wiley VC, Dudman NPB, Wilcken DEL. Free and proteintaining amino acids in plasma and urine after L-methionune
bound homocysteine and cysteine in cystathionine
beta-synthase
loading. Arch Dis Child 1974;49:553-9.
deficiency-interrelations
during
short-term
and long-term
changes in plasma concentrations.
Metab Clin Exp 1989;38:734-9.
40. Beers GHJ, Fowler B, Smals AGH, Trijbels FJM, Leermakers
Al, Kleijer WJ, Kloppenborg PWC. Improved identification of
62. Mansoor MA, Ueland PM, Aarsland A, Svardal AM. Homeheterozygotes
for homocystinuria
due to cyatathionine
synthase
cysteine and other thiols as components of the metabolic derangement in patients with homocystunuria.
Metabolism 1993; (acceptdeficiency by the combination of methionine loading and enzyme
determination in cultured fibroblasts. Hum Genet 1985;69:164-9.
ed).
41. Wilcken DEL, Gupta VJ. Sulphur containing amino acids in
63. Mansoor MA, Guttormeen
AB, Fiskerstrand
T, Refsum H,
chronic renal failure with particular reference to homocystine and
Ueland PM, Svardal AM. Redox status and protein binding of
cysteine-homocysteine
mixed disulphide. Eur J Cliii Invest 1979;
plasma aininothiols during the transient hyperhomocysteinemia
9:301-7.
that follows homocysteine
administration.
Cliii Chem 1993;39:
42. Kong S-S, Wong PWK., Becker N. Protein-bound homocys980-5.
t(e)ine in normal subjects and in patients with homocystinuria.
64. Morgan SL, BaottJE,
Refsum H, Ueland PM. Homocysteine
levels in rheumatoid arthritis patients treated with low-dose
Pediatr Res 1979;13:1141-3.
43. Mansoor MA, Svardal AM, Ueland PM. Determination
of the
methotrexate.
Cliii Pharmacol Ther 1991;50:547-56.
in vivo redox status of cysteine, cysteinylglycine,
homocysteine
65. Stabler SP, Lundenbaum J, Savage DG, Allen RH. Elevation of
and glutathione in human plasma. Anal Biochem 1992;200:218serum cystathionine
levels in patients with cobalamun and folate
29.
deficiency. Blood 1993;81:3403-13.
44. Mansoor MA, Svardal AM, Schneede J, Ueland PM. Dynamic
66. Allen RH, Stabler SP, Lindenbaum
J. Serum betaine, NJ’!dimethylglycine
and N-methylglycine levels in patients with corelation between reduced, oxidized, and protein-bound homocysCLINICAL CHEMISTRY, Vol. 39, No. 9, 1993
1777
balamin and folate deficiency and related inborn errors of metabolism. Metabolism 1993; (in press).
67. Chu RC, Hall CA. The total serum homocysteine as an
indicator of vitamin B12 and folate status. Am J Cliii Pathol
1988;90:446-9.
68. Hyland K, Bottiglieri T. Measurement
of total plasma and
cerebrospunal fluid homocysteine by fluorescence following high.
performance liquid chromatography
and precolumn derivatization
with ortho-phthaldialdehyde. J Chromatogr 1992;579:55-62.
69. Richie JPJ, Lang CA. The determination
of glut.athione,
cyst(e)ine, and other thiols and disulfides in biological samples
using high-performance
liquid chromatography with dual electrochemical detection. Anal Biochem 1987;163:9-15.
70. Demaster EG, Shirota FN, Redfern B, Goon DJW, Nagasawa
HT. Analysis of hepatic reduced glutathione, cysteine and homecysteine by cation-exchange
high-performance
liquid chromatography with electrochemical
detection. J Chromatogr 1984;308:8391.
71. Rabenstein
DL, Yamashita
GT. Determination
of homocysteine, penidilamine,
and their symmetrical and mixed disulfides
by liquid chromatography
with electrochemical
detector. Anal
Biochem 1989;180:259-63.
72. Smolin LA, Sneider JA. Measurement
of total plasma cystsamine using high-performance
liquid chromatography
with electrochemical detection. Anal Biochem 1988;168:374-9.
73. Kong S-S, Wong PWK, Curley K. The effect of D-penicillamine
on protein-bound homocyst(e)ine in homocystinurics.
Pediatr Res
1982;16:370-2.
74. Jocelyn PC. Chemical reduction of disulfides. Methods En-
zymol 1987;143:246-56.
75. Israelsson B, Brattstrom
LE, Hultberg BJ. Homocysteine and
myocardial infarction. Atherosclerosis
1988;71:227-34.
76. Andersson A, Isaksson A, Brattstrom
L, Hultberg B. Homecysteine and other thiols determined
in plasma by HPLC and
thiol-specific
postcolumn
derivatization.
Clin Chem 1993;39:
1590-7.
77. Andersaon A, BrattstrOm L, Israelsson B, Isaksaon A, Hamfelt
A, Hultberg B. Plasma homocysteine before and after methionine
loading with regard to age, gender, and menopausal status. Eur J
Clin Invest 1992;22:79-87.
78. Ubbink JB, Vermask WJH, Vandermerwe
A, Becker PJ. The
effect of blood sample aging and food consumption on plasma total
homocysteine levels. Clin Chim Acta 1992;207:119-28.
79. Andersson A, BrattatrOm
L, Israelsson B, Isakason A, Hultberg B. The effect of excess daily methionune intake on plasma
homocysteine
after a methionine
loading test in humans. Cliii
Chim Acta 1990;192:69-76.
80. Refsum H, Helland 5, Ueland PM. Fasting plasma homocysteine as a sensitive parameter
to antifolate effect. A study on
psoriasis patients receiving low-dose methotrexate
treatment. Clin
Pharmacol Ther 1989;46:510-20.
81. Ueland PM, Refsum H, Svardal AM, Djurhuus R, Helland S.
Perturbation
of homocysteine
metabolism
by pharmacological
agents in experimental
and clinical use. In: Aarbakke J, Chiang
PK, Koeffier HP, eds. Tumor cell differentiation,
biology and
pharmacology.
Clifton, NJ: Humana Press, 1987:269-78.
82. Andersson A, Isaksson A, Hultberg B. Homocysteine export
from erythrocytes and its implication for plasma sampling. Clin
Chem 1992;38: 1311.-S.
83. Svardal A, Refsum H, Ueland PM. Determination of in vivo
protein binding of homocysteine and its relation to free homocysteine in the liver and other tissues of the rat. J Biol Chem
1986;261:3156-63.
84. Young DS, Bermes EW. Specimen collection and processing.
Sources of biological variation. In: Tietz NW, ed. Fundamentals
of
clinical chemistry. Philadelphia:
WB Saunders, 1987:266-86.
85. Brattstrom LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic
acid-an
innocuous means to reduce plasma homocysteine. Scand
J Clin Lab Invest 1988;48:215-21.
86. Boers GH, Smals AG, Trijl)els FJ, Leermakers Al, Kioppenborg PW. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 1983;72:1971-6.
87. Blom HJ, Boers GHJ, van den Elzen JPAM, van Roessel JJM,
Trijbels JMF, Tangerman A. Differences between premenopausal
women and young men in the transamination
pathway of math-
1778 CUNICALCHEMISTRY,Vol. 39, No. 9, 1993
onune catabolism, and the protection against vascular disease. Eur
J Cliii Invest 1988;18:633-8.
88. Brattstr#{246}m
LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal
homocysteinemia.
Metabolism
1985;34:
1073-7.
89. Kang S-S, Wong PWK, Thou J, Cook HY. Preliminsiry report:
total homocyst(e)ine in plasma and amniotic fluid of pregnant
women. Metabolism 1986;35:889-91.
90. Andersson A, Hultberg B, Brattstrom
L, Isaksson A. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin
Biochem 1992;30:377-9.
91. McRae TD, Freedman ML. Why vitamin B12 deficiency should
be managed aggressively. Geriatrics 1989;44:70-9.
92. Cannel R, Sinow RM, Karnaze DS. Atypical cobalamin deficiency-subtle
biochemical
evidence of deficiency is commonly
demonstrated
in patients without megaloblastic
anemia and is
often associated with protein-bound
cobalamin malabsorption.
J
Lab Clin Med 1987;109:454-63.
93. Lindenbaum J, Healton EB, Savage DG, Brust JCM, Garrett
TJ, Podell ER, et al. Neuropsychiatric
disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engi
J Med 1988;318:1720-8.
94. Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical
spectrum and diagnosis of cobalamin deficiency. Blood 1990;76:
871-81.
95. Lindenbaum
J, Savage DG, Stabler SP, Allen RH. Diagnosis
of cobalamin deficiency. II. Relative sensitivities
of serum cobalamin, methylmalonic acid, and total homocysteine concentrations.
Am J Hematol 1990;34:99-107.
96. Carmel R, Sinow RM, Siegel ME, Salmoff IM. Food cobahimin
malabsorption
occurs frequently in patients with unexplained low
serum cobalainin levels. Arch Intern Med 1988;148:1715-9.
97. Matchar DB, Feusaner JR. Laboratory tests in the diagnosis of
vitamin B12 (cobalamin) deficiency. NC Med J 1986;47:118-20.
98. Beck WS. Diagnosis of megaloblastic
anemia. Annu Rev Med
1991;42:311-22.
99. Lindenbaum J, Stabler SP, Allen RH. New assays for cobalamin deficiency getting better specificity. Lab Manage 1988;26:
41-4.
100. Allen RH. Megaloblastic anemia. In: Wyngaarden JB, Smith
LHJ, Bennett JC, Plum F, eds. Cecil textbook of medicine, 19th ad.
Orlando, FL: WB Saunders, 1991:846-54.
101. Savage DG, Lundenbaum J, Stabler SP, Allen RH. Serum
methylmalonic
acid and total homocysteine
in the diagnosis of
deficiencies of cobalamin and folate. Am J Med 1993;(in press).
102. Ermens AAM, Refsum H, Ruprecht J, Spijkers LJM, Guttormsen AB, Lindermans J, eta!. Monitoring cobalamin inactivation during nitrous oxide anesthesia by determination
of homocysteine and folate in plasma and urine. Clin Pharmacol Ther
1991;49:385-93.
103. Cannel R. Subtle and atypical cobalamin deficiency states.
Am J Hematol 1990;34:108-14.
104. Joosten E, van den Berg A, Riezier R, Naurath HJ, Lindenbaum J, Stabler SP, Allen RH. Metabolic evidence that deficiencies
of vitamin B12, folate and vitamin B6 occur commonly in the
elderly. Am J Clin Nutr 1993;(in press).
105. Pennypacker LC, Allen RH, Kelly JP, Matthews M, Grigsby
J, Kaye K, et al. High prevalence of cobalaniin deficiency in elderly
outpatients. J Am Geriatr Soc 1992;40:1197-204.
106 Liii J-Y, Kang S-S. Thou J, Wong PWK Homocysteinemia in
rats induced by folic acid deficiency. Life Sci 1989;33:319-25.
107. Refsum H, Ueland PM, Kvinnsland S. Acute and long-term
effects of high-dose methotrexate treatment
on homocysteine in
plasma and urine. Cancer Res 1986;46:5385-91.
108. Broxson EH, Stork LC, Allen RH, Stabler SP, Koihouse JF.
Changes in plasma methionune and total homocysteine levels in
patients receiving methotrexate
infusions. Cancer Res 1989;49:
5858-62.
109. Refsum H,
in children with
chemotherapeutic
1991;51:828-35.
110. Bailey LB.
11.
111. Savage D,
1986;65:322-38.
Wesenberg F, Ueland PM. Plasma homocysteine
acute lymphoblastic
leukemia. Changes during a
regimen including methotrexate.
Cancer Roe
Folate status assessment.
J Nutr 1990;120:1508-
Lindenbaum
in alcoholics.
J. Anemia
Medicine
112. Brown RD, Jun R, Hughes W, Watman R, Arnold B, Kronenberg H. Red cell folate assay: some answers to current problems
with radioasaay variability. Pathologr 1990;22:82-7.
113. Wickramasinghe
SN, Saunders JE. Results of three years’
experience with the deoxyuridine suppression test. Acta Haematol
1977;58:193-206.
114. Wilcken DEL, Dudman NPB. Homocystinuria
and atherosclerosis [Review]. Monogr Hum Genet 1992;14:311-24.
115. Coull BM, Malinow MR. Beamer N, Sexton G, Nordt F,
Garmo P. Elevated plasma homocyst(e)ine concentration as a
possible independent risk factor for stroke. Stroke 1990;21:572-6.
116. BrattstrOm L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upeon B. Hyperhomocysteinemia
in stroke. Prevalence,
cause and relationship to other risk factors or type of stroke. Eur J
Clin Invest 199222:214-21.
117. Molgaard J, Malinow MR, Lassvik C, Holm A-C, Olsson AG.
Hyperhomocysteinemim an independent risk factor for intermittent claudicatio. J Intern Med 1992;231:273-9.
118. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson
DL, Upeon B. Homocyst(e)inemia
in daily practice: levels in
coronary heart disease. Coronary Artery Dis 1990;1:215-20.
119. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM,
Upson B, Ulnuinn D, at a!. A prospective study of plasma homecyst(e)une and risk of myocardial infarction in United States
physicians. JAm Med Assoc 1992;268:877-81.
120. Soria C, Chadefaux B, Coude M, Gaillard 0, Kamoun P.
Concentrations
of total homocysteine in plasma in chronic renal
failure [Tech Briefi. Cliii Chem 1990;36:2137-8.
121. Chadefaux B, Ceballos I, Hamet M, Coude M, Poissonnier M,
Kamoun P, Allard D. Is absence of atheroma in Down syndrome
due to decreased homocysteine levels? Lancet 1988;ii:741.
122. Refsum H, Ueland PM. Clinical significance of phannacologlea! modulation of homocysteine
metabolism
[Review]. Trends
Pharinacol Sd 1990;11:411-6.
123. Blankenhorn
DR, Malinow ME, Mack WJ. Coleetipol plus
niacin therapy elevates plasma homocyst(e)ine levels. Coronary
Artery Dis 1991;2:357-60.
124. Droll W, Welch AD. Azaribine-homocystinemia-thrombosis
in historical perspectives. Pharmacol Ther 1989;41:195-206.
125. Anonymous. Homocysteine, folk acid, and the prevention of
vascular disease. Nutr Rev 1989;47:247-9.
126. Kong S-S, Wong PWK, Cook LW, Norusis M, Messer JV.
Protein-bound
homocyst(e)ine. A possible risk factor for coronary
artery disease. J Clin Invest 1986;77:1482-6.
127. Araki A, Sake Y, Fukushima
Y, Matsumoto M, Asada T,
Kita T. Plasma sulihydryl-centaining
amino acids in patients with
cerebral infarction and in hypertensive
subjects. Atherosclerosis
1989;79:139-46.
128. Mereau-Richard
C, Muller JP, Faivre E, Ardouin P. Rousseaux L. Total plasma homocysteine
determination
in subjects
with premature
cerebral vascular disease [Letter]. Cliii Chem
1991;37:126.
129. Ubbunk JB, Vermaak WJH, Bennett JM, Becker PJ, van
Staden DA, Bisabort S. The prevalence of homocysteinemia
and
hypercholesterolemia in angiographically
defined coronary heart
disease. Kim Wochenschr
1991;69:527-34.
CUNICAL CHEMISTRY, Vol. 39, No.9, 1993
View publication stats
1779